



Title	Corrigendum to "Risk Factors for Acquisition of Fluoroquinolone or Aminoglycoside Resistance in Addition to Carbapenem Resistance in Pseudomonas aeruginosa"
Author(s)	Kosai, Kosuke; Kaku, Norihito; Uno, Naoki; Saijo, Tomomi; Morinaga, Yoshitomo; Imamura, Yoshifumi; Hasegawa, Hiroo; Miyazaki, Taiga; Izumikawa, Koichi; Mukae, Hiroshi; Yanagihara, Katsunori
Citation	The Open Microbiology Journal, 12, pp.321-322; 2018
Issue Date	2018-09-28
URL	http://hdl.handle.net/10069/38693
Right	© 2018 Kosai et al. This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: (https://creativecommons.org/licenses/by/4.0/legalcode). This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

This document is downloaded at: 2019-02-22T10:31:07Z



The Open Microbiology Journal

Content list available at: www.benthamopen.com/TOMICROJ/

DOI: 10.2174/1874285801812010321, 2018, 12, 321-322



CORRIGENDUM

Risk Factors for Acquisition of Fluoroquinolone or Aminoglycoside Resistance in Addition to Carbapenem Resistance in *Pseudomonas aeruginosa*

Kosuke Kosai^{1,*}, Norihito Kaku², Naoki Uno², Tomomi Saijo³, Yoshitomo Morinaga², Yoshifumi Imamura³, Hiroo Hasegawa¹, Taiga Miyazaki⁴, Koichi Izumikawa⁴, Hiroshi Mukae³ and Katsunori Yanagihara²

¹Department of Laboratory Medicine, Nagasaki University Hospital, Nagasaki, Japan

²Department of Laboratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan

³Department of Respiratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan

⁴Department of Infectious Diseases, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan

Risk Factors for Acquisition of Fluoroquinolone or Aminoglycoside Resistance in Addition to Carbapenem Resistance in *Pseudomonas Aeruginosa*

The Open Microbiology Journal, 2017, 11-92

The correct Table 2 is mentioned below:

Table 2. Univariate and multivariate analyses of risk factors for acquisition of fluoroquinolone or aminoglycoside resistance in addition to imipenem resistance in *Pseudomonas aeruginosa*.

	Univariate analysis			Multivariate analysis		
	OR	95%CI	P	OR	95%CI	P
Resistance to FQs						
Transplantation	1.74	0.80-3.78	0.161			
Use of corticosteroids (≥ 5 mg/day) or other immunosuppressive agents	1.81	0.93-3.52	0.082			
Surgery	0.65	0.35-1.21	0.173			
Exposure to first-generation cephalosporins	0.60	0.30-1.19	0.143			
Exposure to second-generation cephalosporins	0.28	0.08-1.01	0.051			
Exposure to FQs	5.30	2.52-11.14	<0.001	5.73	2.67-12.30	<0.001
Exposure to AGs	3.92	1.30-11.87	0.016			
MBL production	6.67	1.78-24.91	0.005	7.90	2.01-31.04	0.003
Resistance to AGs						
Use of anticancer drugs	2.57	0.64-10.40	0.184			
Use of urinary catheter	0.42	0.13-1.38	0.152			
Exposure to antipseudomonal penicillins	0.24	0.05-1.14	0.073	0.16	0.03-0.89	0.036
Exposure to AGs	6.04	1.59-23.00	0.008	9.00	1.92-42.19	0.005
MBL production	7.35	1.89-28.65	0.004	8.49	1.87-38.52	0.006

OR, odds ratio; CI, confidence interval; FQs, fluoroquinolones; AGs, aminoglycosides; MBL, metallo- β -lactamase

The original table provided was:

Table 2. Proportion of resistant and MBL-producing strains by presence of FQ or AG resistance in imipenem-resistant *Pseudomonas aeruginosa*.

	All strains (n = 169)	Resistance to FQs			Resistance to AGs		
		Yes (n = 66)	No (n = 103)	P	Yes (n = 12)	No (n = 157)	P
Resistance to antibiotics							
Piperacillin ¹⁾	36 (21.3)	21 (31.8)	15 (14.6)	0.003	4 (33.3)	32 (20.4)	0.347
Ceftazidime ¹⁾	53 (31.4)	33 (50.0)	20 (19.4)	<0.001	8 (66.7)	45 (28.7)	0.022
Cefepim	38 (22.5)	28 (42.4)	10 (9.7)	<0.001	7 (58.3)	31 (19.7)	0.006
Aztreonam	91 (53.8)	45 (68.2)	46 (44.7)	0.004	9 (75.0)	82 (52.2)	0.146
Ciprofloxacin ¹⁾	49 (29.0)	-	-	-	8 (66.7)	41 (26.1)	0.011
Levofloxacin	60 (35.5)	-	-	-	6 (50.0)	54 (34.4)	0.350
Gentamicin ¹⁾	12 (7.1)	8 (12.1)	4 (3.9)	0.042	-	-	-
Amikacin ¹⁾	4 (2.4)	3 (4.5)	1 (1.0)	0.274	-	-	-
MBL production	14 (8.3)	11 (16.7)	3 (2.9)	0.003	4 (33.3)	10 (6.4)	0.010

Values are expressed as the number (%).

FQs, fluoroquinolones; AGs, aminoglycosides; MBL, metallo- β -lactamase ¹⁾Minimum inhibitory concentrations (MICs) for piperacillin, ceftazidime, ciprofloxacin, gentamicin and amikacin were not measured in eleven, one, one, one, and thirteen strains, respectively.

© 2018 Kosai *et al.*

This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: (<https://creativecommons.org/licenses/by/4.0/legalcode>). This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.